Keytruda for early-stage melanoma reaches more clinical endpoints
- WHO Releases Global Influenza Vaccine Market Study in 2024
- HIV Infections Linked to Unlicensed Spa’s Vampire Facial Treatments
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
Keytruda for early-stage melanoma reaches more clinical endpoints
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Delaying cancer recurrence: Keytruda for early-stage melanoma reaches more clinical endpoints
On March 07, Merck announced another positive development for its blockbuster immunotherapy Keytruda.
The therapy met key secondary clinical endpoints in clinical trials as adjuvant therapy in resectable stage IIB and IIC melanoma.
Melanoma is one of the most serious types of skin cancer and is characterized by the uncontrolled growth of pigment-producing cells.
Early-stage melanoma can be treated with surgical resection, but melanoma has a high recurrence rate after resection: 32-46% for patients with stage IIB and IIC; 39-74% for patients with stage III %. The five-year survival rate of patients in these three stages is about 80% to 90%.
Keytruda is at the heart of Merck’s early-stage cancer treatment program, which states that treating cancer patients early can lead to better long-term survival. In a phase 3 clinical trial called KEYNOTE-716, researchers enrolled patients with stage IIB and IIC resectable melanoma.
The interim analysis showed that the treatment improved recurrence-free survival (RFS) relative to placebo.
The trial had previously met the primary clinical endpoint of RFS (HR=0.65 [95% CI, 0.46-0.92]; p=0.00658), and the FDA also expanded the indication for Keytruda based on these data.
Today’s results further demonstrate that the therapy, as adjuvant therapy, can statistically significantly improve distant metastasis-free survival (DMFS) with no new safety-signal concerns.
At future medical meetings, Merck plans to present more data.
References:
https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-significant-improvement-in-distant-metastasis-free-survival-dmfs-compared-to-placebo-as-adjuvant-therapy-for-patients-with-resected-stage/
Keytruda for early-stage melanoma reaches more clinical endpoints
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
